Skip to content

Microdosing: all studies

Page 21 of 56: studies 201 to 210 of 555, newest first. Back to the microdosing overview

Research

Facilitating discontinuation of intravenous opioids by -concurrent use of sublingual buprenorphine with rapid microdosing -induction: A pain management case study.

Journal of opioid management 2021 Arjun Tara, Gregory Acampora, Jingping Wang et al.

We report a case in which sublingual buprenorphine was used to help transition a patient off intravenous (IV) opioid analgesics medications post-multiple abdominal procedures. Intravenous opioids are commonly used in inpatient surgical pain management for patients with severe pain who are unable to take oral medications. Typically, a short course of IV analgesics is used, followed by transition...

Successful rotation from long-acting full agonist opioids to sublingual buprenorphine/naloxone using a microdosing approach.

Journal of opioid management 2021 René C Vytialingam, Stephan A Schug, Richard O'Regan

Buprenorphine/naloxone (BPN/NX) is a first-line treatment for opioid use disorder. Conventional treatment guidelines recommend a period of opioid abstinence and the presence of moderate withdrawal before initiation to avoid precipitated withdrawal. A newer approach of "microdosing" removes this requirement and has potential benefits. We present two cases of successful induction of BPN/NX using...

Author response: Self-blinding citizen science to explore psychedelic microdosing

December 11, 2020 Balázs Szigeti, Laura Kärtner, Allan Blemings et al. 1 citation

Psychedelic psychotherapy, therapy enhanced with psychedelic drugs such as LSD or psilocybin (the active ingredient of ‘magic mushrooms’), has been suggested to improve psychological well-being. For this reason, trials on psychedelic therapy for the treatment of depression, addiction and other conditions are ongoing. Recently, ‘microdosing’ – a way of administering psychedelics that involves...

Farmers' Soil Fertility Management in Niger and Opportunities for Improvements Through Mechanization, Microdosing, and Seed Coating

Frontiers in Sustainable Food Systems December 8, 2020 Abdourahamane Issa M. Nourou, Addam Kiari Saidou, Jens B. Aune

The objective of this study was to characterize pearl millet production in Niger and to assess the potential impact of a low-cost production package on land- and labor productivity. The survey showed that 62% of the farmers used manure, while 22% used mineral fertilizer. Of those who used mineral fertilizer only 18% practiced microdosing. High labor demand was given as the reason why 89% of the...

Evaluation of Renal Anionic Secretion Following Living-donor and Deceased-donor Renal Transplantation: A Clinical Pharmacokinetic Study of Cefoxitin Microdosing

Transplantation Direct October 26, 2020 Hari V. Kalluri, Puneet Sood, Wenchen Zhao et al.

Background. Renal transplantation is the treatment of choice for patients with end-stage renal disease. Because kidneys are the primary excretory organs for various drugs/drug metabolites, changes in renal graft function would significantly alter the clearance and exposure of renally secreted drugs. Renal allografts from living and deceased donors normally undergo numerous insults, including...

Microdosing and standard‐dosing take‐home buprenorphine from the emergency department: A feasibility study

Journal of the American College of Emergency Physicians Open October 20, 2020 J. Moe, K. Badke, Megan Pratt et al.

Emergency department (ED)–initiated buprenorphine may prevent overdose. Microdosing is a novel approach that does not require withdrawal, which can be a barrier to standard inductions. We aimed to evaluate the feasibility of an ED‐initiated buprenorphine/naloxone program providing standard‐dosing and microdosing take‐home packages and of randomizing patients to either intervention.

Microdosing psychedelics: Subjective benefits and challenges, substance testing behavior, and the relevance of intention

Journal of Psychopharmacology October 8, 2020 Rotem Petranker, Thomas Anderson, Larissa J. Maier et al. 57 citations

Background: Microdosing psychedelics is the practice of taking small, sub-hallucinogenic doses of lysergic acid diethylamide or psilocybin-containing mushrooms. Despite its surging popularity, little is known about the specific intentions to start microdosing and the effects of this practice. Aims: First, we aimed to replicate previous findings regarding the subjective benefits and challenges...

Potential safety, benefits, and influence of the placebo effect in microdosing psychedelic drugs: A systematic review

Neuroscience & Biobehavioral Reviews October 5, 2020 Genís Ona, José Carlos Bouso 59 citations

Microdosing psychedelic drugs-that is, taking sub-behavioral doses of lysergic acid diethylamide (LSD) or psilocybin-is a growing practice in Western societies. Taken mainly for creative or mood-enhancing purposes, thousands of users are increasingly being exposed to (micro)doses of psychedelic drugs. In this systematic review, we searched the available evidence from human studies, focusing our...

Transitioning From Intrathecal Hydromorphone to Sublingual Buprenorphine–Naloxone Through Microdosing: A Case Report

A&A Practice September 21, 2020 Isaiah T. Crum, VaKara M. Meyer Karre, Alëna A. Balasanova

A 76-year-old woman with chronic noncancer pain and an intrathecal hydromorphone–bupivacaine pump was admitted for acute exacerbation of heart failure. Her pump was unable to be replaced due to medical comorbidities. She was unable to tolerate oral opioids due to ventilatory depression. Tapering hydromorphone resulted in opioid withdrawal due to physiological dependence. Microdosing of...

Phase 0/microdosing approaches: time for mainstream application in drug development?

Nature Reviews Drug Discovery September 8, 2020 Tal Burt, Graeme C. Young, Wooin Lee et al. 101 citations

Phase 0 approaches - which include microdosing - evaluate subtherapeutic exposures of new drugs in first-in-human studies known as exploratory clinical trials. Recent progress extends phase 0 benefits beyond assessment of pharmacokinetics to include understanding of mechanism of action and pharmacodynamics. Phase 0 approaches have the potential to improve preclinical candidate selection and...